ETCTN 10366: A phase 1 study of DNA-PK inhibitor peposertib in combination with hypofractionated radiotherapy for the treatment of locally advanced pancreatic adenocarcinoma

被引：0
|
作者：
Davis, S. Lindsey
Kasi, Anup
Dayyani, Farshid
Ocean, Allyson J.
Chung, Vincent
Al Hallak, Mohammed Najeeb
Fountzilas, Christos
Hu, Junxiao
Murray, Judy
Allegra, Carmen
Gore, Steven
Beumer, Jan Hendrik
Goodman, Karyn A.
机构：
[1] Univ Colorado, Canc Ctr, Aurora, CO USA
[2] Univ Kansas, Canc Ctr, Westwood, KS USA
[3] Univ Calif Irvine, Chao Family Comprehens Canc Ctr, Orange, CA 92668 USA
[4] NewYork Presbyterian Weill Cornell Med Ctr, New York, NY USA
[5] City Hope Comprehens Canc Ctr, Duarte, CA USA
[6] Wayne State Univ, Karmanos Canc Inst, Detroit, MI USA
[7] Roswell Park Comprehens Canc Ctr, Buffalo, NY USA
[8] Johns Hopkins Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
[9] NCI, Bethesda, MD 20892 USA
[10] UPMC Hillman Canc Ctr, Pittsburgh, PA USA
[11] Icahn Sch Med Mt Sinai, Dept Radiat Oncol, New York, NY 10029 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4168
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A multicenter phase Ib/II study of DNA-PK inhibitor peposertib (M3814) in combination with capecitabine and radiotherapy in patients with locally advanced rectal cancer.
    Romesser, Paul Bernard
    Holliday, Emma B.
    Philip, Tony
    Sarholz, Barbara
    Kuipers, Mirjam
    Rodriguez-Gutierrez, Almudena
    Diaz-Padilla, Ivan
    Miller, Eric David
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [2] A multicenter phase Ib/II study of DNA-PK inhibitor peposertib (M3814) in combination with capecitabine and radiotherapy in patients with locally advanced rectal cancer.
    Romesser, Paul Bernard
    Holliday, Emma B.
    Philip, Tony
    Garcia-Carbonero, Rocio
    Capdevila, Jaume
    Tuli, Richard
    Sarholz, Barbara
    Kuipers, Mirjam
    Rodriguez, Almudena
    Diaz-Padilla, Ivan
    Miller, Eric David
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [3] A Phase Ib Study of the DNA-PK Inhibitor Peposertib Combined with Neoadjuvant Chemoradiation in Patients with Locally Advanced Rectal Cancer
    Romesser, Paul B.
    Capdevila, Jaume
    Garcia-Carbonero, Rocio
    Philip, Tony
    Martos, Carlos Fernandez
    Tuli, Richard
    Rodriguez-Gutierrez, Almudena
    Kuipers, Mirjam
    Becker, Andreas
    Coenen-Stass, Anna
    Sarholz, Barbara
    You, Xiaoli
    Miller, Eric D.
    CLINICAL CANCER RESEARCH, 2024, 30 (04) : 695 - 702
  • [4] A Phase 1 Study of the DNA-PK Inhibitor Peposertib in Combination With Radiation Therapy With or Without Cisplatin in Patients With Advanced Head and Neck Tumors
    Samuels, Michael
    Falkenius, Johan
    Bar -Ad, Voichita
    Dunst, Juergen
    van Triest, Baukelien
    Yachnin, Jeffrey
    Rodriguez-Gutierrez, Almudena
    Kuipers, Mirjam
    You, Xiaoli
    Sarholz, Barbara
    Locatelli, Giuseppe
    Becker, Andreas
    Troost, Esther G. C.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 118 (03): : 743 - 756
  • [5] A phase II study of hypofractionated radiotherapy in combination with Gemcitabin in the palliative treatment of advanced pancreatic carcinoma
    Antonisse, IE
    van Groeningen, CJ
    Langendijk, JA
    Slotman, BJ
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S141 - S141
  • [6] A phase 1 study of veliparib, a PARP-1/2 inhibitor, with gemcitabine and radiotherapy in locally advanced pancreatic cancer
    Tuli, R.
    Shiao, S. L.
    Nissen, N.
    Tighiouart, M.
    Kim, S.
    Osipov, A.
    Bryant, M.
    Ristow, L.
    Placencio-Hickok, V. R.
    Hoffman, D.
    Rokhsar, S.
    Scher, K.
    Klempner, S. J.
    Noe, P.
    Davis, M. J.
    Wachsman, A.
    Lo, S.
    Jamil, L.
    Sandler, H.
    Piantadosi, S.
    Hendifar, A.
    EBIOMEDICINE, 2019, 40 : 375 - 381
  • [7] GEMOX plus hypofractionated radiotherapy for unresectable locally advanced pancreatic cancer: Results from a phase II study
    Passardi, A.
    Scarpi, E.
    Neri, E.
    Parisi, E.
    Ghigi, G.
    Ercolani, G.
    Gardini, A.
    La Barba, G.
    Pagan, F.
    Gardini, A. Casadei
    Frassineti, L. G.
    Ferroni, F.
    Valgiusti, M.
    Darwish, S. A. M. Z. M.
    Romeo, A.
    ANNALS OF ONCOLOGY, 2018, 29 : 249 - 249
  • [8] A Phase I Study of Hypofractionated Stereotactic Radiotherapy and Concurrent HIV Protease Inhibitor Nelfinavir as part of a Neoadjuvant Regimen in Patients with Locally Advanced Pancreatic Cancer
    Lin, C.
    Sasson, A. R.
    Ly, Q. P.
    Kos, M. E.
    Schwarz, J. K.
    Are, C.
    Chen, S.
    Sehi, E. D.
    Enke, C. A.
    Grem, J. L.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011, 81 (02): : S68 - S68
  • [9] Phase 1 study of hypofractionated radiation in combination with tremelimumab and durvalumab in refractory metastatic pancreatic adenocarcinoma.
    O'Hara, Mark H.
    Bear, Adham S.
    Wattenberg, Max M.
    Teitelbaum, Ursina R.
    Reiss, Kim A.
    Karasic, Thomas B.
    Schneider, Charles J.
    O'Dwyer, Peter J.
    Ben-Josef, Edgar H.
    Wojcieszynski, Andrzej P.
    Maity, Amit H.
    Mick, Rosemarie H.
    Vonderheide, Robert H.
    CANCER RESEARCH, 2022, 82 (22) : 8 - 9
  • [10] A Radiation Dose Escalation Study of Hyperfractionated Accelerated Radiotherapy in Combination with Daily S1 in Patients with Locally Advanced Pancreatic Adenocarcinoma
    Hiraki, Y.
    Nakamura, F.
    Ito, S.
    Arimura, T.
    Nakajo, M.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011, 81 (02): : S333 - S334
12345